Healthcare Providers and Services
Company Overview of Onco360
Onco360 provides oncology pharmaceuticals and care management services for physicians, patients, payers, and pharmaceutical manufacturers in the United States. It offers OncoSource, a total sourcing solution that offers drug pedigree, and no clinical fragmentation (oral, injected, infused, and limited distribution products); OncoDose, a fulfillment model that delivers treatment day/dose dispensing, as well as stat and emergency dose capabilities; OncoMTM, a medication treatment management program that helps improve safety, reduce adverse events, and drive compliance. The company also provides OncoPaths, which facilitates concordance with pathways subject to NCCN, ASCO, or payer evidence-base...
410 Park Avenue
New York, NY 10022
Founded in 2003
Key Executives for Onco360
Chief Executive Officer and President
Founder, Managing Partner and Director of Clinical Programs
Scientific Advisory Council Partner
Scientific Advisory Council Partner
Compensation as of Fiscal Year 2016.
Onco360 Key Developments
Taiho Oncology, Inc Selects Onco360 as Limited Distribution Pharmacy Network Participant for Lonsurf
Oct 7 15
Onco360 announced that it has been selected by Taiho Oncology Inc. (Taiho) as a limited distribution pharmacy network participant for LONSURF®(trifluridine and tipiracil). With the addition of LONSURF, Onco360 continues to grow its broad portfolio of limited distribution oncology medications. LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Pfizer, Inc Selects Onco360 as Limited Distribution Pharmacy Provider
Feb 9 15
Onco360 announced that it has been selected by Pfizer Inc. as a limited distribution pharmacy network participant for Ibrance (palbociclib), Pfizer's recently approved product for certain breast cancers. The addition of this medication marks another key product win for Onco360, which continues to grow its portfolio of limited distribution products.
Onco360 Plans to Close its Corporate Headquarters in Manhattan; to Invest About $2 million to Build Out and Equip 25,000 Square Feet of the Jeffersontown Facility for the New Headquarters
Feb 2 15
Onco360 plans to close its corporate headquarters in Manhattan and relocate it to Louisville summer 2015. The company chose Louisville because the city's transportation network allows it to quickly transport its products anywhere. Bad weather, including heavy snow storms, are more common in the Northeast, and they can bring transportation networks to a halt. Jardina said some current employees will relocate to Louisville from New York and other parts of the country, but most of the 150 jobs will come from company growth. The company will keep a presence in the Northeast by maintaining its pharmacy hub in Great Neck, N.Y.
The company will invest about $2 million to build out and equip 25,000 square feet of the Jeffersontown facility for the new headquarters, which is expected to house 150 employees within the next 10 years. Onco360 has committed to creating 30 jobs within the first year of operation. KEDFA has preliminarily awarded the company $1.6 million in tax incentives.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|